In this episode, Anthony and Bernie are joined by special guest, Dr. Justin Kaner from Weill Cornell Medicine, to discuss some of the most interesting ASH abstracts in leukemia in 2025! What abstracts should change practice? Listen to find out.

Some of the abstracts discussed:

• PARADIGM: https://meetings-api.hematology.org/api/abstract/vmpreview/296881
• KMT2A Outcomes (MARROW Consortium and Othman, et al.): https://meetings-api.hematology.org/api/abstract/vmpreview/302582 and https://meetings-api.hematology.org/api/abstract/vmpreview/297333
• CLIA +/- Ven: https://meetings-api.hematology.org/api/abstract/vmpreview/302047
• FLT3i studies (and MRD): https://meetings-api.hematology.org/api/abstract/vmpreview/295719 and https://meetings-api.hematology.org/api/abstract/vmpreview/302699 and https://meetings-api.hematology.org/api/abstract/vmpreview/291322
• ALL GIMEMA Trial (blin + ponatinib): https://meetings-api.hematology.org/api/abstract/vmpreview/296532
• Menin inhibitor data

Anthony and Bernie discuss the PARADIGM study that was presented at the plenary session of ASH 2025 and whether results should change our practice.

https://meetings-api.hematology.org/api/abstract/vmpreview/296881

In this study, Bernie and Anthony are joined by the majestic myeloma man Manni Mohyuddin to discuss key ASH abstracts in myeloma, including the results of the MajesTEC-3 study!